Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive KarXT in Inadequately Controlled Schizophrenia
NCT05145413Phase 3Completed
- Sponsor
- Karuna Therapeutics
- Start
- Nov 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing KarXT with Placebo (2 arms). Primary endpoint: Positive and Negative Syndrome Scale Total Score at 6 weeks. Started Nov 2021; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05145413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145413.